Degarelix 80mg Injection$190.00
1–9 boxes
$190.00 each
10–24 boxes
8% off
25+ boxes
10% off
Degarelix 80mg Injection
SKU GME1351Oncology Care
Product Introduction
Degarelix 80mg is a GnRH antagonist for hormone-dependent prostate cancer. It rapidly suppresses testosterone without the initial testosterone surge associated with GnRH agonists.
How to use
The reconstituted medicine is injected under the abdominal skin by a clinical team, away from areas subject to pressure. It must not be given into a vein or muscle. Loading and maintenance presentations follow different dose plans.
How it works
Degarelix blocks pituitary GnRH receptors, reducing LH and FSH release and thereby lowering testicular testosterone production.
Side effects
Injection-site pain or swelling, hot flushes, weight change and increased liver enzymes can occur. Long-term androgen deprivation can affect bone density and glucose control.
Important information
Monitor PSA and testosterone response. Heart-rhythm risk, diabetes and fracture risk are relevant. Degarelix is not a treatment for women or children.
Uses
- Hormone-dependent prostate cancer in an appropriate androgen-deprivation regimen.
Benefits
Rapid testosterone suppression can control androgen-driven cancer activity without an initial tumour-flare surge.
Are the 80mg and 120mg vials used in the same way?
No. The usual initial course uses two 120mg injections, followed by 80mg maintenance injections. Presentation and schedule must match the intended phase.
Will testosterone rise briefly before it falls?
A GnRH antagonist suppresses it directly, avoiding the initial surge typical of agonists.
Can treatment affect bone strength?
Prolonged testosterone suppression can reduce bone density, so fracture prevention is part of ongoing care.
Why are both PSA and testosterone measured?
They provide different information: testosterone shows hormonal suppression, while PSA helps assess disease response.
GnRH antagonist: a medicine that directly blocks pituitary GnRH receptors. LH: luteinising hormone. Tumour flare: transient symptom worsening from an initial hormone surge.; AR: Degarelix 80mg حقن; FR: Degarelix 80mg injection; PT: Degarelix 80mg injeção; ES: Degarelix 80mg inyección; RU: Degarelix 80mg инъекция; ID: Degarelix 80mg suntikan; VI: Degarelix 80mg thuốc tiêm; MS: Degarelix 80mg suntikan; TL: Degarelix 80mg iniksyon; ZH-SG: Degarelix 80mg 注射剂